Dara Biosciences (DARA) 0.88 $DARA DARA BioSciences wins

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dara Biosciences (DARA) 0.88 $DARA

DARA BioSciences wins stockholder's approval of merger with and into Midatech
M2 - Thu Dec 03, 5:27AM CST
DARA BioSciences (NasdaqCMARA) reported on Wednesday the receipt of stockholders' approval for the adoption of the merger agreement by and among DARA, Midatech Pharma PLC (Midatech) and certain other parties thereto.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Stockholder Approval of Merger With Midatech
Marketwired - Wed Dec 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC ("Midatech" and certain other parties thereto.
DARA: 0.88 (-0.06)

DARA BioSciences posts higher loss of USD2.7m for Q3 2015
M2 - Tue Nov 03, 4:21AM CST
Pharmaceutical company DARA BioSciences (NasdaqCMARA) disclosed on Monday that it recorded a loss attributable to controlling interest of approximately USD2.7m (USD0.14 per share) for the third quarter ended 30 September 2015.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Third Quarter 2015 Results
Marketwired - Mon Nov 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015
Marketwired - Tue Oct 06, 7:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA) today announced that it will be featured as a presenting company at the 2015 Aegis Growth Conference, sponsored by Aegis Capital Corp. The Aegis Growth Conference, which will feature growth companies in Healthcare, Technology, Telecom and Aerospace-Defense sectors, will be held October 7-9, 2015 at The Encore at Wynn Hotel in Las Vegas, NV. DARA BioSciences is an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment.
DARA: 0.88 (-0.06)

DARA BioSciences unveils Oravig (miconazole) in the oncology and primary care markets in the US for treatment of adults with oral thrush
M2 - Tue Oct 06, 4:36AM CDT
Specialist pharmaceutical company DARA BioSciences (NasdaqCMARA) reported on Monday the availability of Oravig, the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush, into the oncology and primary care markets in the US.
DARA: 0.88 (-0.06)

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush
Marketwired - Mon Oct 05, 7:01AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today the U.S. launch of Oravig -- the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush -- into the Oncology and Primary Care markets. Beginning this week, DARA and its marketing partner Mission Pharmacal Company, a privately held pharmaceutical company based in San Antonio, TX, will simultaneously begin promotion of Oravig with two separate sales forces focusing on the highest prescribing physicians of oral thrush therapy; DARA will promote Oravig exclusively in Oncology with its 20 person nationwide sales force and Mission will utilize its 40 person-strong sales team to promote the product exclusively to the Primary Care market. DARA was granted exclusive U.S. rights to Oravig in March 2015, under a Commercialization Agreement with Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
Marketwired - Wed Sep 23, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Ladenburg Thalmann 2015 Healthcare conference. The conference is being held September 29, 2015, at the Sofitel Hotel in New York City.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015
Marketwired - Wed Sep 02, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Rodman and Renshaw Global Investment Conference. The conference is being held September 8-10, 2015, at the Saint Regis Hotel in New York City.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Second Quarter 2015 Results
Marketwired - Wed Aug 12, 3:15PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results
Marketwired - Mon Aug 10, 7:00AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2015, after the close of the market on Wednesday, August 12, 2015.
DARA: 0.88 (-0.06)

Robbins Arroyo LLP: Acquisition of DARA BioSciences, Inc. (DARA) by Midatech Pharma Plc (MTPH) May Not Be in Shareholders' Best Interests
PR Newswire - Thu Jun 25, 2:49PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of DARA BioSciences Inc. (NASDAQ: DARA) by Midatech Pharma Plc (London: MTPH). On June 4, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Midatech will acquire DARA. Under the terms of the agreement, DARA shareholders will receive 0.272 shares of Midatech for each share of DARA they own, the value of which is equivalent to $1.20 per share of DARA common stock.
DARA: 0.88 (-0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 43

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 73

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 19

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 0

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 108

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 14

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 94

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 77

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 20

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Experiences Coming to Myrtle Beach in 2025

Updated Category News Views 1799

Discover What's New and Exciting in Myrtle Beach Fresh, unique adventures await at The Beach. As one of the Southeast's most beloved travel destinations, Myrtle Beach is gearing up for an exciting new year filled with unforgettable new and expanded experiences, alongside its iconic offerings that continue to draw visitors to its golden shores from across the nation. With...

Continue Reading
NXP Semiconductors Showcases Strong Energy and Growth Initiatives

Updated Category News Views 250

NXP Semiconductors Posts Impressive Q3 2025 Financial Results NXP Semiconductors N.V. (NASDAQ: NXPI) has announced its financial results for the third quarter, revealing a revenue of $3.17 billion. This performance exceeded market expectations and places NXP in a strong position amidst improving economic conditions. The company's president, Rafael Sotomayor, highlighted...

Continue Reading
Red Pine Exploration Secures Significant Funding Through Placement

Updated Category News Views 81

Red Pine Exploration Announces Major Funding Initiative Today, Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) has captured attention with its announcement of a significant C$7.0 million private placement. This deal, arranged by Haywood Securities Inc. and Research Capital Corporation, sets the stage for the company’s growth while bolstering its gold exploration...

Continue Reading
Ken Griffin Critiques Trump's Tariff Policies Impacting Economy

Updated Category News Views 172

Ken Griffin's Strong Critique of Tariff Policies Ken Griffin, known as the CEO of Citadel LLC, has emerged as a vocal critic of former President Donald Trump's tariff policy, labeling it as detrimental to the American economy. Griffin's stance marks a significant shift from his previous support for Trump, and he is urging for a reevaluation of the existing economic...

Continue Reading
Investigation Launched into Spyre Therapeutics by Pomerantz

Updated Category News Views 175

Pomerantz LLP Investigates Spyre Therapeutics, Inc. Pomerantz LLP is currently conducting an investigation on behalf of investors in Spyre Therapeutics, Inc. (NASDAQ: SYRE). This investigation seeks to uncover whether the company, along with its officials and directors, has engaged in fraudulent activities or other illicit business practices. Investors who believe they...

Continue Reading